Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (539 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 7.398, 5-year impact factor: 7.575
Url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973641543&doi=10.1016%2fj.cgh.2015.12.049&partnerID=40&md5=194fb70fb6ef84a3bb4aa78af0c290a0
Keywords: Adpkd Volume, Cyst Growth, Somatostatin Analogue,
Affiliations:
*** IBB - CNR ***
Nephrology Units, Department of Public Health, Federico II University, Naples, Italy., Department of Radiology, Federico II University, Naples, Italy., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy., Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy., Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy., Department of Surgical Sciences and Nephrology, Federico II University, Naples, Italy., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address: Giuseppe.remuzzi@marionegri.it., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.,
References:
Not available.
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 7.398, 5-year impact factor: 7.575
Url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973641543&doi=10.1016%2fj.cgh.2015.12.049&partnerID=40&md5=194fb70fb6ef84a3bb4aa78af0c290a0
Keywords: Adpkd Volume, Cyst Growth, Somatostatin Analogue,
Affiliations:
*** IBB - CNR ***
Nephrology Units, Department of Public Health, Federico II University, Naples, Italy., Department of Radiology, Federico II University, Naples, Italy., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy., Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy., Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy., Department of Surgical Sciences and Nephrology, Federico II University, Naples, Italy., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address: Giuseppe.remuzzi@marionegri.it., IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Clinical Research Centre for Rare Diseases "Aldo e Cele Dacco", Bergamo, Italy; Nephrology and Dialysis Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.,
References:
Not available.
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease
BACKGROUND & AIMS: Short-term studies have shown that somatostatin analogues are effective in patients with polycystic kidney and liver disease. We evaluated the long-term effects of long-acting release octreotide (octreotide LAR), a somatostatin inhibitor, vs placebo in these patients. METHODS: We performed a prospective study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m2 or more) at a single center in Italy. We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years. The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended. RESULTS: Baseline characteristics were similar between groups. After 3 years, TLV decreased by 130.2 +/- 133.2 mL in patients given octreotide LAR (7.8% +/- 7.4%) (P = .003) but increased by 144.3 +/- 316.8 mL (6.1% +/- 14.1%) in patients given placebo. Change vs baseline differed significantly between groups (P = .004). Two years after treatment ended, TLV had decreased 14.4 +/- 138.4 mL (0.8% +/- 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 +/- 331.7 mL (11.0% +/- 14.4%) in patients given placebo. Changes vs baseline still differed significantly between groups (P = .046). Decreases in TLV were similar in each sex; the change in TLV was greatest among subjects with larger baseline TLV. No patient withdrew because of side effects. CONCLUSIONS: In a placebo-controlled study of patients with polycystic kidney and liver disease, 3 years of treatment with octreotide LAR significantly reduced liver volume; reductions were maintained for 2 years after treatment ended. Octreotide LAR was well-tolerated. ClinicalTrials.gov number: NCT02119052.
BACKGROUND & AIMS: Short-term studies have shown that somatostatin analogues are effective in patients with polycystic kidney and liver disease. We evaluated the long-term effects of long-acting release octreotide (octreotide LAR), a somatostatin inhibitor, vs placebo in these patients. METHODS: We performed a prospective study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m2 or more) at a single center in Italy. We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years. The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended. RESULTS: Baseline characteristics were similar between groups. After 3 years, TLV decreased by 130.2 +/- 133.2 mL in patients given octreotide LAR (7.8% +/- 7.4%) (P = .003) but increased by 144.3 +/- 316.8 mL (6.1% +/- 14.1%) in patients given placebo. Change vs baseline differed significantly between groups (P = .004). Two years after treatment ended, TLV had decreased 14.4 +/- 138.4 mL (0.8% +/- 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 +/- 331.7 mL (11.0% +/- 14.4%) in patients given placebo. Changes vs baseline still differed significantly between groups (P = .046). Decreases in TLV were similar in each sex; the change in TLV was greatest among subjects with larger baseline TLV. No patient withdrew because of side effects. CONCLUSIONS: In a placebo-controlled study of patients with polycystic kidney and liver disease, 3 years of treatment with octreotide LAR significantly reduced liver volume; reductions were maintained for 2 years after treatment ended. Octreotide LAR was well-tolerated. ClinicalTrials.gov number: NCT02119052.
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease
No results. |
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease
Other filter: ([btitle,keywords] "Adpkd Volume" OR [bt ...
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (273 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (572 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (853 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (273 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (572 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (853 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
3 Records (2 excluding Abstracts).
Total impact factor: 9.167 (5.63 excluding Abstracts).
Total 5 year impact factor: 9.8 (6.172 excluding Abstracts).
Total impact factor: 9.167 (5.63 excluding Abstracts).
Total 5 year impact factor: 9.8 (6.172 excluding Abstracts).
539 views. Last view on Friday 06 December 2024, 21:18:09
ibb.cnr.it
